Summary of CPACS potential opportunity, the proposed P1/P2 allcomers trial is focused on Doxorubicin basket trial for CPACS/FTO.
The Triangle report, places sales for US (only) Doxorubicin - Breast Cancer treatments at $1.7b USD p.a. It doesn't consider all indications and global sales / CPACS / FTO, which is where this gets farfetched if you extrapolate sales potential for other indications.
The following are implied opportunities from research reports, historical clinical trials, various assumptions so not to be relied on DYOR not advice. Props to @johndprent (Post #: 73756269) and @Mason14 (Post #: 73390872) I can't take credit for the summary.
Source: Triangle Report (app.sharelinktechnologies.com/announcement/asx/e0c332e661c11f781398af97fd2fe108)
Summary of CPACS potential opportunity, the proposed P1/P2...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $245.4M | |||
| Open | High | Low | Value | Volume |
| $1.47 | $1.51 | $1.43 | $122.3K | 82.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 69 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.44 |
Change
0.010 ( 1.71 %) |
||||
| Open | High | Low | Volume | ||
| $1.49 | $1.50 | $1.43 | 16871 | ||
| Last updated 15.58pm 27/05/2024 ? | |||||
| RAC (ASX) Chart |